Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ)
CNY 5.25
(-2.42%)
CNY 5.25
(-2.42%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 895.59 Million CNY | -0.95% |
| 2022 | 884.58 Million CNY | -27.8% |
| 2021 | 1.22 Billion CNY | -22.63% |
| 2020 | 1.58 Billion CNY | -14.82% |
| 2019 | 1.85 Billion CNY | 18.99% |
| 2018 | 1.56 Billion CNY | 21.86% |
| 2017 | 1.28 Billion CNY | 29.47% |
| 2016 | 990.21 Million CNY | 2.72% |
| 2015 | 963.97 Million CNY | 5.72% |
| 2014 | 911.8 Million CNY | 20.11% |
| 2013 | 759.11 Million CNY | 20.22% |
| 2012 | 631.46 Million CNY | 18.23% |
| 2011 | 534.09 Million CNY | 41.43% |
| 2010 | 377.64 Million CNY | 13.22% |
| 2009 | 333.54 Million CNY | 25.76% |
| 2008 | 265.22 Million CNY | 59.72% |
| 2007 | 166.05 Million CNY | 72.12% |
| 2006 | 96.47 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 195.75 Million CNY | 8.08% |
| 2024 Q3 | 223.89 Million CNY | 14.38% |
| 2024 Q1 | 181.12 Million CNY | -26.32% |
| 2023 Q3 | 190.89 Million CNY | -15.98% |
| 2023 Q4 | 245.8 Million CNY | 28.76% |
| 2023 Q2 | 227.2 Million CNY | 0.24% |
| 2023 FY | 876.17 Million CNY | -0.95% |
| 2023 Q1 | 226.65 Million CNY | 6.05% |
| 2022 Q1 | 198.7 Million CNY | -40.42% |
| 2022 Q2 | 207.72 Million CNY | 4.54% |
| 2022 Q3 | 264.42 Million CNY | 27.29% |
| 2022 Q4 | 213.73 Million CNY | -19.17% |
| 2022 FY | 884.58 Million CNY | -27.8% |
| 2021 Q4 | 333.52 Million CNY | 19.23% |
| 2021 FY | 1.22 Billion CNY | -22.63% |
| 2021 Q2 | 251.68 Million CNY | -30.14% |
| 2021 Q3 | 279.73 Million CNY | 11.14% |
| 2021 Q1 | 360.28 Million CNY | -29.62% |
| 2020 Q2 | 350.04 Million CNY | 40.83% |
| 2020 Q4 | 511.9 Million CNY | 8.22% |
| 2020 Q1 | 248.56 Million CNY | -55.61% |
| 2020 FY | 1.58 Billion CNY | -14.82% |
| 2020 Q3 | 473 Million CNY | 35.13% |
| 2019 Q3 | 503.65 Million CNY | 4.35% |
| 2019 FY | 1.85 Billion CNY | 18.99% |
| 2019 Q1 | 312.72 Million CNY | -37.71% |
| 2019 Q2 | 482.64 Million CNY | 54.33% |
| 2019 Q4 | 559.98 Million CNY | 11.18% |
| 2018 FY | 1.56 Billion CNY | 21.86% |
| 2018 Q4 | 502.05 Million CNY | 35.06% |
| 2018 Q3 | 371.73 Million CNY | 2.75% |
| 2018 Q2 | 361.78 Million CNY | 10.71% |
| 2018 Q1 | 326.79 Million CNY | -21.53% |
| 2017 Q1 | 246.23 Million CNY | -18.75% |
| 2017 Q3 | 334.5 Million CNY | 17.42% |
| 2017 FY | 1.28 Billion CNY | 29.47% |
| 2017 Q4 | 416.44 Million CNY | 24.49% |
| 2017 Q2 | 284.87 Million CNY | 15.69% |
| 2016 FY | 990.21 Million CNY | 2.72% |
| 2016 Q1 | 246.85 Million CNY | -11.56% |
| 2016 Q2 | 200.43 Million CNY | -18.8% |
| 2016 Q3 | 239.87 Million CNY | 19.68% |
| 2016 Q4 | 303.05 Million CNY | 26.34% |
| 2015 Q2 | 204.75 Million CNY | -13.48% |
| 2015 Q1 | 236.65 Million CNY | -24.6% |
| 2015 Q3 | 243.43 Million CNY | 18.9% |
| 2015 FY | 963.97 Million CNY | 5.72% |
| 2015 Q4 | 279.13 Million CNY | 14.66% |
| 2014 Q3 | 243.89 Million CNY | 23.4% |
| 2014 Q4 | 313.86 Million CNY | 28.69% |
| 2014 Q2 | 197.64 Million CNY | 26.37% |
| 2014 Q1 | 156.39 Million CNY | -29.68% |
| 2014 FY | 911.8 Million CNY | 20.11% |
| 2013 Q4 | 222.39 Million CNY | 23.58% |
| 2013 Q3 | 179.96 Million CNY | -2.3% |
| 2013 Q2 | 184.19 Million CNY | 6.74% |
| 2013 Q1 | 172.56 Million CNY | 7.25% |
| 2013 FY | 759.11 Million CNY | 20.22% |
| 2012 FY | 631.46 Million CNY | 18.23% |
| 2012 Q3 | 144.75 Million CNY | -15.67% |
| 2012 Q2 | 171.64 Million CNY | 11.33% |
| 2012 Q4 | 160.89 Million CNY | 11.15% |
| 2012 Q1 | 154.17 Million CNY | 11.17% |
| 2011 Q2 | 131.89 Million CNY | -8.69% |
| 2011 FY | 534.09 Million CNY | 41.43% |
| 2011 Q1 | 144.44 Million CNY | 35.9% |
| 2011 Q4 | 138.68 Million CNY | 16.46% |
| 2011 Q3 | 119.07 Million CNY | -9.72% |
| 2010 Q1 | 93.81 Million CNY | 2.18% |
| 2010 Q3 | 87.32 Million CNY | -3.21% |
| 2010 Q4 | 106.28 Million CNY | 21.71% |
| 2010 FY | 377.64 Million CNY | 13.22% |
| 2010 Q2 | 90.22 Million CNY | -3.83% |
| 2009 FY | 333.54 Million CNY | 25.76% |
| 2009 Q4 | 91.81 Million CNY | 2.85% |
| 2009 Q3 | 89.27 Million CNY | 9.2% |
| 2009 Q2 | 81.75 Million CNY | 15.63% |
| 2009 Q1 | 70.7 Million CNY | 3.39% |
| 2008 FY | 265.22 Million CNY | 59.72% |
| 2008 Q4 | 68.38 Million CNY | -2.59% |
| 2008 Q3 | 70.2 Million CNY | 0.0% |
| 2007 FY | 166.05 Million CNY | 72.12% |
| 2006 FY | 96.47 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 32.05 Billion CNY | 97.206% |
| Zhejiang Zhenyuan Share Co., Ltd. | 4.1 Billion CNY | 78.19% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 656.89 Million CNY | -36.338% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 737.81 Million CNY | -21.384% |
| Yifan Pharmaceutical Co., Ltd. | 4.02 Billion CNY | 77.734% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 533.23 Million CNY | -67.955% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 21.15 Billion CNY | 95.766% |
| Boai NKY Medical Holdings Ltd. | 1.58 Billion CNY | 43.439% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 848.19 Million CNY | -5.589% |